Evidence supporting the use of: EPA (eicosapentaenoic acid)
For the health condition: Osteoporosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid primarily found in fish oil. Its use in osteoporosis management is based on emerging scientific evidence rather than strong traditional usage. Several preclinical and clinical studies suggest that omega-3 fatty acids, particularly EPA, may exert beneficial effects on bone metabolism. Mechanistically, EPA is believed to reduce inflammation by modulating the production of pro-inflammatory cytokines, which can negatively affect bone resorption and formation. Animal studies have demonstrated that diets enriched with EPA can result in increased bone mineral density (BMD) and improved bone microarchitecture. Human observational studies and a few randomized controlled trials have reported modest positive associations between higher omega-3 intake and BMD or reduced fracture risk, especially in older adults.

However, the clinical evidence remains limited and somewhat inconsistent. Most available studies have small sample sizes, short durations, or combine EPA with other nutrients (such as DHA or vitamin D), making it difficult to isolate EPA's specific effects. Systematic reviews and meta-analyses generally conclude that while there is some promise, more robust and well-designed clinical trials are needed to confirm the efficacy of EPA supplementation for osteoporosis prevention or treatment. As such, EPA's use in osteoporosis is scientifically motivated, but the strength of evidence is currently moderate to low, justifying a rating of 2 on the evidence scale.

More about EPA (eicosapentaenoic acid)
More about Osteoporosis